There are several advantages to using perfusion in your seed train, namely, flexibility in your production processes, increase in capacity and footprint reduction. Reducing the number of bioreactors in your seed train leads to a better utilization and eliminates traditional bottlenecks (compressed seed train). Additionally, using N-1 perfusion enables the inoculation of a production bioreactor with higher cell densities for high seed production process formats. Cellvento^® 4CHO-X Expansion Medium has been specifically developed for N-1 perfusion for Chinese Hamster Ovary (CHO) cell lines. It is formulated with a high nutrient concentration to achieve low cell specific perfusion rates (CSPRs) at high cell densities. The medium is chemically defined, of non-animal origin, and contains no hydrolysates or components of unknown composition.

Cellvento^® 4CHO-X Expansion Medium has been specifically formulated to control the metabolic profile of the cells, both to minimize toxic byproducts and to ensure adequate nutrient levels for high cell densities. Preventing nutrient depletion can increase robustness and predictability of seed train operations. This medium supports high growth and viability, thus increasing cell biomass for cryopreservation or inoculation of another reactor. The medium addresses seed train intensification and shows a positive impact in IgG production, when combined in perfusion production with EX-CELL^® Advanced HD Perfusion medium (24370C), and in Fed-batch production with e.g. Cellvento^® 4CHO medium (103795) and Cellvento^® 4Feed (103796). It is expected to work with other media platforms as well. Cellvento^® 4CHO-X Expansion Medium can be used for all seed train expansion steps including N-1, reaching robust growth at low CSPRs. This product is intended for research or further manufacturing but not for human or therapeutic use.

Formulated to contain 26.2 grams of powder per liter of medium.

CELLVENTO is a registered trademark of Merck KGaA, Darmstadt, Germany

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany